TERT and TET2 Genetic Variants Affect Leukocyte Telomere Length and Clinical Outcome in Coronary Artery Disease Patients-A Possible Link to Clonal Hematopoiesis.
Trine B OpstadSvein SolheimAlf-Åge R PettersenAre A KalstadHarald ArnesenIngebjørg SeljeflotPublished in: Biomedicines (2022)
Inherited and acquired mutations in hematopoietic stem cells can cause clonal expansion with increased risk of cardiovascular disease (CVD), a condition known for the clonal hematopoiesis of indeterminate potential (CHIP). Inherited genetic variants in two CHIP-associated genome loci, the telomerase gene telomerase enzyme reverse transcriptase (TERT) (rs7705526) and the epigenetic regulator ten-eleven translocation 2 (TET2) (rs2454206), were investigated in 1001 patients with stable coronary artery disease (CAD) (mean age 62 years, 22% women), with regards to cardiovascular outcome, comorbidities, and leukocyte telomere length. Over 2 years, mutated TERT increased the risk two-fold for major clinical events (MACEs) in all patients ( p = 0.004), acute myocardial infarction (AMI) in male patients ( p = 0.011), and stroke in female patients ( p < 0.001). Mutated TET2 correlated with type 2 diabetes ( p < 0.001), the metabolic syndrome ( p = 0.002), as well as fasting glucose, HbA1c, and shorter telomeres ( p = 0.032, p = 0.003, and p = 0.016, respectively). In conclusion, our results from stable CAD patients highlight TERTs' role in CVD, and underline TET2s' role in the epigenetic regulation of lifestyle-related diseases.
Keyphrases
- coronary artery disease
- end stage renal disease
- cardiovascular disease
- stem cells
- ejection fraction
- acute myocardial infarction
- newly diagnosed
- prognostic factors
- heart failure
- gene expression
- patient reported outcomes
- bone marrow
- type diabetes
- insulin resistance
- high throughput
- high resolution
- blood pressure
- single cell
- acute coronary syndrome
- mesenchymal stem cells
- skeletal muscle
- blood glucose
- high speed
- aortic valve
- glycemic control